中美福(fu)源成立于2015年(nian)1月26日(有限(xian)公司成立于2010年(nian)3月10日),公司主要從事醫藥產品、技術的(de)開發以及轉讓(rang)自(zi)有技術。
公(gong)(gong)(gong)司(si)(si)控股(gu)3個子(zi)(zi)公(gong)(gong)(gong)司(si)(si),分別是北(bei)京美福源生(sheng)(sheng)物醫藥(yao)科(ke)技(ji)有(you)(you)限公(gong)(gong)(gong)司(si)(si)、天(tian)津林達生(sheng)(sheng)物科(ke)技(ji)有(you)(you)限公(gong)(gong)(gong)司(si)(si)和(he)天(tian)津溥瀛生(sheng)(sheng)物技(ji)術有(you)(you)限公(gong)(gong)(gong)司(si)(si)。這(zhe)3個子(zi)(zi)公(gong)(gong)(gong)司(si)(si)在股(gu)份公(gong)(gong)(gong)司(si)(si)中分別承擔(dan)著新(xin)藥(yao)研(yan)發(fa)的不(bu)同(tong)研(yan)究(jiu)內容和(he)階(jie)段性工作。公(gong)(gong)(gong)司(si)(si)與(yu)子(zi)(zi)公(gong)(gong)(gong)司(si)(si)一(yi)道(dao)以(yi)在中國(guo)開展(zhan)(zhan)原(yuan)創原(yuan)研(yan)國(guo)家1類新(xin)藥(yao)的臨床前研(yan)究(jiu)、臨床試驗(yan)研(yan)究(jiu)和(he)產業化作為公(gong)(gong)(gong)司(si)(si)的主營業務。公(gong)(gong)(gong)司(si)(si)正在開展(zhan)(zhan)中的原(yuan)創原(yuan)研(yan)新(xin)藥(yao)均是以(yi)現(xian)有(you)(you)重組蛋白(bai)質藥(yao)物的長效化新(xin)藥(yao)研(yan)發(fa)為重點。公(gong)(gong)(gong)司(si)(si)與(yu)子(zi)(zi)公(gong)(gong)(gong)司(si)(si)共同(tong)擁(yong)有(you)(you)這(zhe)個新(xin)藥(yao)研(yan)發(fa)技(ji)術平臺。
公司還有(you)合(he)資公司:天津福盈(ying)生物制藥有(you)限公司。
公司(si)于2015年7月30日在新三板掛牌成功;證(zheng)券簡稱:中美(mei)福源,證(zheng)券代碼(ma):833178。